Business
BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates
$194.5 million in total first quarter revenues, comprised of $180.6 million of U.S. Attruby® net product revenue, with strong prescribing growth and patient persistence driving continued commercial momentumContinued broad uptake among all patient types and HCP segments with particularly strong and growing demand in treatment naïve patients; global launch gaining traction with recent Brazil approvalReal-world evidence reinforces the differentiation demonstrated in trial data. Analysis recently re
About this update from Bridgebio Pharma, Inc.
[{"type":"image","alt":"BridgeBio Pharma, Inc.","displaySize":"","headline":null,"caption":"BridgeBio Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":47,"url":"https://media.zenfs.com/en/globenewswire.com/67d229c5dfa70aa930ee69ce2872e9be"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rIWtRfd.HYOh2kEpGfi40w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY2/https://media.zenfs.com/en/globenewswire.com/67d229c5dfa70aa930ee69ce2872e9be","width":300,"height":47},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/rIWtRfd.HYOh2kEpGfi40w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY2/https://media.zenfs.com/en/globenewswire.com/67d229c5dfa70aa930ee69ce2872e9be","width":300,"height":47}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"$194.5 million in total first quarter revenues, comprised of $180.6 million of U.S. Attruby® net product revenue, with strong prescribing growth and patient persistence driving continued commercial momentum","length":206,"tagName":"p"}]},{"val":[{"type":"text","content":"Continued broad uptake among all patient types and HCP segments with particularly strong and growing demand in treatment naïve patients; global launch gaining traction with recent Brazil approval","length":195,"tagName":"p"}]},{"val":[{"type":"text","content":"Real-world evidence reinforces the differentiation demonstrated in trial data. Analysis recently released on medRxiv.org shows Attruby reduces diuretic intensification by 43% compared to tafamidis; in addition, an independent real world evidence study presented at SCAI also revealed statistically significant outcome improvements associated with acoramidis as compared to tafamidis (Jahan, Valley Health System)","length":412,"tagName":"p"}]},{"val":[{"type":"text","content":"BridgeBio submitted its first of three planned NDAs to the FDA for BBP-418 in LGMD2I/R9; on track for the other NDAs for encaleret in ADH1 to be submitted in 1H 2026 and for oral infigratinib in achondroplasia to be submitted in Q3 2026. All three programs may be eligible for priority review","length":292,"tagName":"p"}]},{"val":[{"type":"text","content":"$940.2 million in cash, cash equivalents, and marketable securities as of March 31, 2026","length":88,"tagName":"p"}]},{"val":[{"type":"text","content":"The Board of Directors authorized a share repurchase program of up to $500...